Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

abstract：BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

journal_title：Current cancer drug targets

authors： Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

更新日期：2019-01-01 00:00:00

abstract：:Polysialic acid (polySia) is a carbohydrate polymer critical for neuronal cell migration and axon pathfinding in embryonic development. Besides brain regions requiring persistent neuronal plasticity, polySia is essentially absent from the adult body. However, polySia is aberrantly re-expressed on many tumours, where i...

journal_title：Current cancer drug targets

authors： Falconer RA,Errington RJ,Shnyder SD,Smith PJ,Patterson LH

更新日期：2012-10-01 00:00:00

abstract：:There is an emerging paradigm shift in oncology that seeks to emphasize molecularly targeted approaches for cancer prevention and therapy. Chalcones (1,3-diphenyl-2-propen-1-ones), naturally-occurring compounds with widespread distribution in spices, tea, beer, fruits and vegetables, consist of open-chain flavonoids i...

journal_title：Current cancer drug targets

authors： Jandial DD,Blair CA,Zhang S,Krill LS,Zhang YB,Zi X

更新日期：2014-01-01 00:00:00

abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

journal_title：Current cancer drug targets

authors： Donkena KV,Yuan H,Young CY

更新日期：2010-06-01 00:00:00

abstract：:Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

journal_title：Current cancer drug targets

authors： Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

更新日期：2013-07-01 00:00:00

abstract：:Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...

journal_title：Current cancer drug targets

authors： Liang Z,Lu Z,Zhang Y,Shang D,Li R,Liu L,Zhao Z,Zhang P,Lin Q,Feng C,Zhang Y,Liu P,Tu Z,Liu H

更新日期：2019-01-01 00:00:00

abstract：:Despite remarkable progress that has been made in the recent years in the treatment of gastrointestinal tumors, in particular colorectal cancer, the prognosis of pancreatic cancer remains dismal. Five years after diagnosis almost all patients have died. At early stages of the disease surgery is the only modality to ac...

journal_title：Current cancer drug targets

authors： Porzner M,Seufferlein T

更新日期：2011-07-01 00:00:00

abstract：:Exosomes are small vesicles that are secreted by various types of cells, known to mediate signal transduction between cells. During recent years, novel carriers for the delivery of targeted drugs, chemotherapy drugs and RNAs are under development, which is believed to be beneficial for patients. Considering issues of ...

journal_title：Current cancer drug targets

authors： Wang X,Zhang H,Yang H,Bai M,Ning T,Li S,Li J,Deng T,Ying G,Ba Y

更新日期：2018-01-01 00:00:00

abstract：:Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

journal_title：Current cancer drug targets

authors： Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

更新日期：2003-12-01 00:00:00

abstract：:One of the challenges of cancer therapeutics is to discover targets unique to the tumor cell population. Constitutively activated tyrosine kinases play a role in the malignant phenotype in a number of different cancers. While the kinases may be present in the normal cell, the cancer cell is often dependent upon the ac...

journal_title：Current cancer drug targets

authors： Ritchie E,Nichols G

更新日期：2006-12-01 00:00:00

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：:Wild-type Wilms' tumor gene WT1 is expressed at high levels not only in most of acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, but also in various types of solid tumors including lung cancer. We tested the ability of the gene product (WT1) to serve as a target antigen for tumor specific immunot...

journal_title：Current cancer drug targets

authors： Oka Y,Tsuboi A,Elisseeva OA,Udaka K,Sugiyama H

更新日期：2002-03-01 00:00:00

abstract：:The Jun oncoprotein is a major component of the transcription factor complex AP-1, which regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Constitutive activation of endogenous AP-1 is required for tumor formation in avian and mammalian cell transformation syst...

journal_title：Current cancer drug targets

authors： Hartl M,Bader AG,Bister K

更新日期：2003-02-01 00:00:00

abstract：:The actin microfilament network is important in maintaining cell shape and function in eukaryotic cells. It has a multitude of roles in cellular processes such as cell adhesion, motility, cellular signalling, intracellular trafficking and cytokinesis. Alterations in the organisation of the cytoskeleton and changes in ...

journal_title：Current cancer drug targets

authors： Stehn JR,Schevzov G,O'Neill GM,Gunning PW

更新日期：2006-05-01 00:00:00

abstract：:Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of these agents suffer clinic...

journal_title：Current cancer drug targets

authors： Mayur YC,Peters GJ,Prasad VV,Lemo C,Sathish NK

更新日期：2009-05-01 00:00:00

abstract：:Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membran...

journal_title：Current cancer drug targets

authors： Grunt TW,Mariani GL

更新日期：2013-02-01 00:00:00

abstract：:The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of phar...

journal_title：Current cancer drug targets

authors： Liu Y,Lou C,Yang H,Shi M,Miyoshi H

更新日期：2011-02-01 00:00:00

abstract：:Malignant brain tumors including primary brain tumors (e.g., glioblastoma multiforme) and metastases, are aggressive and lethal entities for the majority of affected patients. Current standard treatments involving combinations of surgery, radiotherapy and systemic chemotherapy offer only modest improvements in surviva...

journal_title：Current cancer drug targets

authors： Drapeau A,Fortin D

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) is a well-recognised drug target exploited for treating non-small cell lung cancer (NSCLC). Gefitinib and erlotinib are first generation clinically employed inhibitors used against EGFR activating mutants. However, during course of treatment these inhibitors become ine...

journal_title：Current cancer drug targets

authors： Agarwal SM,Pal D,Gupta M,Saini R

更新日期：2017-01-01 00:00:00

abstract：:Anchorage-independent growth, anoikis resistance, and most steps of metastasis formation are integrin-mediated or -dependent processes, which are characteristics of malignant tumor cells. Acting as oncogenes or tumor suppressor genes, integrins may be involved in the oncogenic transformation of normal cells and their ...

journal_title：Current cancer drug targets

authors： Eble JA,Haier J

更新日期：2006-03-01 00:00:00

abstract：:Histone deacetylase inhibitors (HDACi) belong to a novel class of drugs able to act on the epigenome, indirectly remodeling the spatial conformation of the chromatin: by increasing histone acetylation these drugs ultimately promote the detachment of the DNA from the nucleosome octamer, therefore allowing the access of...

journal_title：Current cancer drug targets

authors： Rodriguez-Menendez V,Tremolizzo L,Cavaletti G

更新日期：2008-06-01 00:00:00

abstract：:Human mesenchymal stem cells (hMSCs) consist of cells that can differentiate into mesenchymal tissues, including osteoblasts, adipocytes and chondrocytes. hMSCs constitute a particular stem cell niche in the stromal compartment of the bone marrow, and also play a role in maintaining the normal function of haematopoiet...

journal_title：Current cancer drug targets

authors： Cruet-Hennequart S,Prendergast AM,Barry FP,Carty MP

更新日期：2010-06-01 00:00:00

abstract：:Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

journal_title：Current cancer drug targets

authors： Gnant M

更新日期：2009-11-01 00:00:00

abstract：:Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determine...

journal_title：Current cancer drug targets

authors： Duverna R,Ablordeppey SY,Lamango NS

更新日期：2010-09-01 00:00:00

abstract：:Gardenia, the fruit of Gardenia jasminoides Ellis, has been widely used to treat liver and gall bladder disorders in Chinese medicine. It has been shown recently that geniposide, the main ingredient of Gardenia Fructus, exhibits the anti-tumor effect. In this review, we discuss the anti-tumor effect and possible mecha...

journal_title：Current cancer drug targets

authors： Peng CH,Huang CN,Wang CJ

更新日期：2005-06-01 00:00:00

abstract：:Targets for cancer therapy are conventionally selected by identification of molecules acting downstream of established tumour suppressors and oncoproteins, such as p53, c-Myc and Ras. However, the forward genetics approach provides an alternative, conceptually distinct, strategy for identifying target molecules de nov...

journal_title：Current cancer drug targets

authors： Mourtada-Maarabouni M,Watson D,Munir M,Farzaneh F,Williams GT

更新日期：2013-01-01 00:00:00

abstract：:Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

journal_title：Current cancer drug targets

authors： Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

更新日期：2013-09-01 00:00:00

abstract：:Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recen...

journal_title：Current cancer drug targets

authors： Hardcastle J,Kurozumi K,Chiocca EA,Kaur B

更新日期：2007-03-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00

abstract：:Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the uni...

journal_title：Current cancer drug targets

authors： Tandon I,Sharma NK

更新日期：2019-01-01 00:00:00